Get started
Live feed
·
PRReleasevia Quantisnow
Iovance Biotherapeutics Inc. logo

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

ByQuantisnow·Wall Street's wire, on your screen.
IOVAIovance Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IOVA (Iovance Biotherapeutics Inc.) and more on Quantisnow.